Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis

被引:1
|
作者
Yuste, C. [1 ,15 ]
Passerat, V. [2 ,3 ]
Calais, G. [3 ,4 ]
Schipman, B. [5 ]
Vaugier, L. [6 ]
Paumier, A. [1 ]
Huertas, A. [7 ]
Hemery, C. G. [8 ]
Debelleix, C. [9 ]
Chamois, J. [10 ]
Blanchard, N. [11 ]
Septans, AL. [12 ]
Pointreau, Y. [3 ,4 ,12 ,13 ,14 ]
机构
[1] Inst Cancerol Ouest, Angers, France
[2] Ctr Bayard, Villeurbanne, France
[3] Colib Club Oncologues Liberaux, Le Mans, France
[4] Oncol & Radiotherapie CORAD, Tours, France
[5] Inst Cancerol Bourgogne, Dijon, France
[6] Inst Cancerol Ouest, St Herblain, France
[7] Inst Radiotherapie Sud Oise, Creil, France
[8] Polyclin Courlancy, Reims, France
[9] Clin Bordeaux Tivoli Ducos, Bordeaux, France
[10] Private Hosp, Saint Gregoire, France
[11] Clin Dentellieres, Valenciennes, France
[12] Weprom, Angers, France
[13] Ctr Jean Bernard, Inst Interreg Cancerol ILC, Le Mans, France
[14] Ctr Cancerol Sarthe CCS, Le Mans, France
[15] Inst Cancerol Ouest, 15 Rue Andre Boquel, F-49055 Angers, France
关键词
Stereotactic body radiation therapy; Oligometastasis; Adrenal gland; Local control; Survival; Prognostic factors; OLIGOMETASTASES; CRITERIA;
D O I
10.1016/j.ctro.2023.100708
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The adrenal gland is a common site of metastasis with a rate of up to 27% in autopsy series. The incidence of these metastases is increasing due to greater use of Positron Emission Tomography scans and improved overall survival of patients with metastatic cancers. Stereotactic body radiation therapy (SBRT) is a non-invasive treatment option for metastasis. The aim of this study is to assess prognostic factors influencing local control, progression-free and overall survival in oligometastatic patients treated with SBRT for an adrenal metastasis. Methods: In this multicentric retrospective study, we included patients with adrenal metastases treated with SBRT between 2010 and 2021 in eleven french centers. All primary tumors were included. Results: A total of 110 patients treated for 121 adrenal lesions were included. Non-small-cell lung cancer was the predominant histologic type (55.4 %). Eighty-two percent of patients had at least 2 metastatic sites. The median Planning Target Volume was 70 cm3 with a median prescription dose of 40 Gray (Gy). The mean Biologically Effective Dose (BED) 10 dose was 74.2 Gy. Local control at 1 and 2 years was 85.9 % and 72.5 % respectively. The median overall survival and progression-free survival were 31.6 and 8.5 months respectively. Local control was significantly improved by systemic treatment one month before or after SBRT (p = 0.009) and by a BED10 greater than or equal to 50 Gy (p = 0.003). In multivariate analysis, oligometastatic presentation (p = 0.009) and a metachronous metastatic presentation (p = 0.008) were independent factors for progression-free survival. Tolerance was excellent, no grade 3 and 4 toxicities were described due to SBRT. Conclusion: Stereotactic radiotherapy of adrenal metastases makes possible a local control of more than 85% at one year and was well tolerated. The factors influencing survival in oligometastatic patients still need to be found in order to better select those who benefit the most from this type of treatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival Analysis
    Bui, D. L.
    Magnuson, W. J.
    Lester-Coll, N. H.
    Qian, J. M.
    Ross, R.
    Soulos, P. R.
    Shafman, T. D.
    Dosoretz, A. P.
    Evans, S. B.
    Yu, J. B.
    Gross, C. P.
    Decker, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E443 - E443
  • [22] Stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis
    Ehret, Felix
    Kaul, David
    Kufeld, Markus
    Endt, Clara Vom
    Budach, Volker
    Fuerweger, Christoph
    Haidenberger, Alfred
    Muacevic, Alexander
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 91 - 91
  • [23] Multi-institutional Analysis of Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases: High Rates of Local Control with Favorable Toxicity
    Baumann, B. C.
    Bernstein, K. D.
    Levin, W. P.
    DeLaney, T. F.
    Kolker, J. D.
    Choy, E.
    Weber, K.
    Muniappan, A.
    Berman, A. T.
    Staddon, A.
    Hartner, L.
    Van Tine, B. A.
    Hahn, S. M.
    Glatstein, E. J.
    Simone, C. B., II
    Nagda, S.
    Chen, Y. L. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S77 - S78
  • [24] Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
    Reshko, Leonid B.
    Gaskins, Jeremy T.
    Silverman, Craig L.
    Dunlap, Neal E.
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2021, 26 (03) : 325 - 340
  • [25] Single Institution Experience with Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
    Koong, A.
    Toesca, D. A. S.
    Von Eyben, R.
    Koong, A. C.
    Chang, D. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E91 - E92
  • [26] STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR ADRENAL METASTASES
    Menichelli, C.
    Masciullo, S.
    Bonucci, I.
    Doro, R.
    Masi, L.
    Casamassima, E.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S368 - S368
  • [27] Hypofractionated stereotactic body radiation therapy for adrenal metastases
    Dupic, G.
    Biau, J.
    Belliere-Calandry, A.
    Lapeyre, M.
    CANCER RADIOTHERAPIE, 2017, 21 (05): : 428 - 428
  • [28] A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck
    Singh, Raj
    Jenkins, Jan
    Davis, Joanne
    Song, Shiyu
    Sharma, Sanjeev
    Vargo, John Austin
    JOURNAL OF RADIOSURGERY AND SBRT, 2022, 8 (01): : 11 - 19
  • [29] Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis
    Ehret, Felix
    Kaul, David
    Kufeld, Markus
    Vom Endt, Clara
    Budach, Volker
    Senger, Carolin
    Fuerweger, Christoph
    Haidenberger, Alfred
    Muacevic, Alexander
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1095 - 1101
  • [30] Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis
    Felix Ehret
    David Kaul
    Markus Kufeld
    Clara vom Endt
    Volker Budach
    Carolin Senger
    Christoph Fürweger
    Alfred Haidenberger
    Alexander Muacevic
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1095 - 1101